Theratechnologies Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals

Montreal, sept. 20, 2023 (globe newswire) -- theratechnologies inc. (“theratechnologies” or the “company”) (tsx: th) (nasdaq: thtx), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that mr. paul lÉvesque, president and chief executive officer, will participate in a panel presentation at the cantor fitzgerald global healthcare conference 2023 being held september 26-28 in new york city.

Montreal, sept. 18, 2023 (globe newswire) -- theratechnologies inc. (“theratechnologies” or the “company”) (tsx: th) (nasdaq: thtx), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced the company will report financial results and provide a business update for its third quarter ended august 31, 2023, on tuesday, september 26 at 8:30 a.m. edt.

Montreal, aug. 30, 2023 (globe newswire) -- theratechnologies inc. (“theratechnologies” or the “company”) (tsx: th) (nasdaq: thtx), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that all five of the u.s.-based clinical sites participating in the conduct of the phase 1 clinical trial of the company's lead investigational peptide drug conjugate, sudocetaxel zendusortide, are now activated to screen, enroll and dose advanced ovarian cancer patients. a sixth site based in canada is finalizing its start-up activity.

Toronto , aug. 21, 2023 /prnewswire/ - paul lÉvesque, president and chief executive officer, hamilton thorne ltd. ("theratechnologies", the "company", or "we") (tsx: th) shares his company's story in an  interview  with tmx group.

Montreal, july 31, 2023 (globe newswire) -- theratechnologies inc. (“theratechnologies”, the “company”, or “we”) (tsx: th) (nasdaq: thtx), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it has completed the previously announced consolidation of the issued and outstanding common shares of the company's share capital on the basis of one (1) post- consolidation share for each four (4) pre-consolidation shares issued and outstanding (the “consolidation”).

MONTREAL, Sept. 20, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that Mr. Paul Lévesque, President and Chief Executive Officer, will participate in a panel presentation at the Cantor Fitzgerald Global Healthcare Conference 2023 being held September 26-28 in New York City.

MONTREAL, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced the Company will report financial results and provide a business update for its third quarter ended August 31, 2023, on Tuesday, September 26 at 8:30 a.m. EDT.

MONTREAL, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that Paul Lévesque, President and Chief Executive Officer, will present at the H.C. Wainwright 25th Annual Global Investment Conference, to be held virtually and in person on September 11-13, 2023, in New York City at the Lotte New York Palace Hotel.

MONTREAL, June 29, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced it will report financial results and provide a business update for its second quarter ended May 31, 2023, on Wednesday, July 12 at 8:30 a.m. EDT.

MONTREAL, May 25, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced preliminary efficacy data from a Phase 1 study of its lead investigational peptide-drug conjugate (PDC) candidate, sudocetaxel zendusortide (formerly TH1902), in patients with advanced solid tumors. In a June 3 poster session at the 2023 annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago, researchers will present early results from Part 1 (dose escalation) and Part 2 (dose expansion) of the multicenter, open-label trial of sudocetaxel zendusortide, in which 36% of heavily pretreated participants experienced a clinical benefit, including two patients with partial responses (PR) and seven achieving prolonged stable disease (SD).

Montreal, Quebec--(Newsfile Corp. - April 18, 2023) - Theratechnologies (NASDAQ: THTX) (TSX: TH), a biopharmaceutical company focused on the development and commercialization of innovative therapies, will be participating in the 2023 Bloom Burton & Co. Healthcare Investor Conference, which will take place on April 25 and 26 at the Metro Toronto Convention Centre. Dates: Tuesday April 25, 2023-Wednesday April 26, 2023 Time: 8:30 AM-4:30 PM ET Location:  Metro Toronto Convention Centre, North Building 255 Front St W Toronto, Ontario M5V 2W6   Paul Levesque will be speaking at 11:30 ET on April 25th.

Theratechnologies (TSX:TH) Inc shares continued to advance Friday, up 12% to $1.29 following a 10% gain on Thursday, after the biopharmaceutical company announced that it expects its fiscal year 2023 revenue to be in the range of between $90 million and $95 million, representing commercial portfolio growth of between 13% and 19% over the past year. Theratechnologies (TSX:TH) also reported that its first quarter 2023 consolidated revenue rose 7.3% year-over-year to US$19,908,000, as sales of EGRIFTA SV reached US$12,711,000 and Trogarzo sales increased 5% to US$7,197,000 during the period.

Theratechnologies Inc. (NASDAQ:THTX ) Q1 2023 Earnings Conference Call April 12, 2023 8:30 AM ET Company Participants Elif McDonald - Head of Investor Relations Paul Levesque - President and Chief Executive Officer John Leasure - Global Commercial Officer Philippe Dubuc - Chief Financial Officer Christian Marsolais - Chief Medical Officer Conference Call Participants Louise Chen - Cantor Justin Walsh - JonesTrading Edward Nash - Canaccord Genuity Endri Leno - National Bank Operator Good morning, ladies and gentlemen, and thank you for standing by. Welcome to Theratechnologies First Quarter Fiscal Year 2023 Earnings Call.

Theratechnologies (TSX:TH) has reported first-quarter financial results with consolidated revenue growing by 7% to US$19.9mln. The Montreal-headquartered biopharmaceutical firm told investors that the performance was supported by a 9% growth in revenue from the EGRIFTA SV product along with 5% growth for Trogarzo which are both used by patients with HIV.

MONTREAL, April 03, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (TSX: TH) (NASDAQ: THTX) (“Theratechnologies”), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it will report financial results for its first quarter 2023 ended February 28, on Wednesday, April 12, 2023.